证券代码：688622 证券简称：禾信仪器 公告编号：2025-048 广州禾信仪器股份有限公司 股东昆山市国科创业投资有限公司（以下简称"昆山国科"或"出让方"） 保证向广州禾信仪器股份有限公司（以下简称"公司"或"禾信仪器"）提供的 信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确 性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ? 拟参与禾信仪器首发前股东询价转让（以下简称"本次询价转让"）的股 东为昆山国科； ? 出让方拟转让股份的总数为 1,303,612 股，占公司总股本的比例为 1.85%； ? 本次询价转让为非公开转让，不通过集中竞价交易方式或大宗交易方式 进行，不属于通过二级市场减持。受让方通过询价转让受让的股份，在受让后 6 个月内不得转让； ? 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中国国际金融股份有限公司（以下简称"中金公司"）组织实施 本次询价转让。截至 2025 年 8 月 25 日，出让 ...

南京国博电子股份有限公司 股东询价转让计划书 股东天津丰荷科技合伙企业（有限合伙）保证向南京国博电子股份有限公司提供的信息内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ● 拟参与南京国博电子股份有限公司（以下简称"国博电子"或"公司"）首发前股东询价转让（以下简 称"本次询价转让"）的股东为天津丰荷科技合伙企业（有限合伙）（以下简称"天津丰荷"或"出让 方"）； ● 出让方拟转让股份的总数为14,900,373股，占国博电子总股本的比例为2.50%； ● 本次询价转让不通过集中竞价交易或大宗交易方式进行，不属于通过二级市场减持。受让方通过询价 转让受让的股份，在受让后6个月内不得转让； ● 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资者。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688375 证券简称：国博电子 公告编号：2025-025 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中信建投证券股份有限公司 ...

Summary of Key Points Core Viewpoint - The announcement details a share transfer plan involving the shareholders of Longxin Zhongke Technology Co., Ltd., indicating a non-public transfer of 5,498,219 shares, which represents 1.37% of the total share capital, to institutional investors due to the shareholders' funding needs [1][3][4]. Group 1: Shareholder Information - The transferring shareholders include Beijing Tiantong Xinyuan Investment Management Center, Beijing Tiantong Xinzhen Technology Development Center, and Beijing Tiantong Xinguo Technology Development Center, collectively referred to as the "transferors" [1]. - The transferors are acting in concert with the controlling shareholder Tiantong Xinyuan, which holds over 5% of the total share capital [1][2]. Group 2: Transfer Details - The total number of shares to be transferred is 5,498,219, accounting for 1.37% of the total share capital [3]. - The transfer will be conducted through a non-public method, and the shares acquired by the buyers cannot be transferred within six months [3][4]. - The minimum transfer price will be set at no less than 70% of the average trading price over the 20 trading days prior to the invitation for subscription [4]. Group 3: Investor Eligibility - Eligible buyers for the share transfer include institutional investors with appropriate pricing capabilities and risk tolerance, such as securities companies, fund management companies, and qualified foreign investors [5]. Group 4: Company Status - Longxin Zhongke does not face any operational risks or potential changes in control due to this share transfer [6]. - There are no undisclosed significant matters related to the company that could impact the transfer [6].

Core Viewpoint - Hanghua Ink Co., Ltd. is undergoing a share transfer process where its shareholder, T&K TOKA, plans to transfer 12,603,855 shares, representing 3.00% of the total share capital, due to personal funding needs [1][5] Group 1: Share Transfer Details - The share transfer will be a non-public transfer, and the shares cannot be transferred by the acquirer within six months after the acquisition [1] - The minimum transfer price is set at no less than 70% of the average stock price over the previous 20 trading days prior to the invitation [1] - The transfer is being organized by China International Capital Corporation (CICC) [1] Group 2: Shareholder Qualifications - T&K TOKA, established in 1949, is a non-controlling shareholder of Hanghua and has no restrictions on the shares being transferred [2] - The company has complied with all necessary review and approval procedures for the share transfer [2] Group 3: Pricing and Demand - The preliminary transfer price is set at 7.09 yuan per share, with 14 institutional investors participating in the bidding process [3] - The total number of shares effectively subscribed by these investors is 16,030,000, indicating a subscription multiple of approximately 1.27 times [3] - The final results of the share transfer will depend on the processing by the Shanghai branch of China Securities Depository and Clearing Corporation [3] Group 4: Compensation Progress - Hanghua has received a total of 38,896.33 million yuan in relocation compensation, with the second payment amounting to 7,779.266 million yuan recently received [4][5] - The company will account for these payments according to the relevant accounting standards, with no significant impact expected on the 2025 annual performance [4]

Core Viewpoint - Dongguan Dingtong Precision Technology Co., Ltd. is planning a pre-IPO share transfer through a non-public inquiry transfer, with a total of 4,176,000 shares, representing 3.00% of the company's total equity [2][7]. Group 1: Share Transfer Details - The transferring shareholder is Dongguan Dinhong Junsheng Investment Co., Ltd., which is the controlling shareholder of Dingtong Technology [3]. - The shares being transferred have been released from restrictions and are free of any transfer limitations [3][5]. - The transfer is motivated by the shareholder's need for funds [7]. Group 2: Transfer Pricing and Conditions - The minimum transfer price will not be lower than 70% of the average trading price over the 20 trading days prior to July 31, 2025 [8]. - If the total valid subscriptions exceed the number of shares available, the transfer price will be determined based on price priority, quantity priority, and time priority [9]. - The transfer is open to institutional investors with appropriate pricing capabilities and risk tolerance [10].

Core Viewpoint - The shareholders of Guangdong Weide Information Technology Co., Ltd. plan to transfer a total of 3,350,936 shares, representing 4.00% of the company's total equity, through a pre-IPO inquiry transfer process [3][5]. Group 1: Shareholder Transfer Details - The shareholders involved in the transfer include Wei Xiujun, Guangzhou Weiteng Investment Partnership, Chen Rui, and Zhang Chun [3]. - Wei Xiujun intends to transfer 2,071,418 shares (2.47% of total equity), Weiteng Partnership 553,957 shares (0.66%), Chen Rui 394,612 shares (0.47%), and Zhang Chun 330,949 shares (0.40%) [3]. - The transfer will not occur through centralized bidding or block trading, and the shares acquired through this transfer cannot be sold within six months [3]. Group 2: Shareholder Background - None of the transferring shareholders are the controlling shareholders or actual controllers of Weide Information [4]. - Wei Xiujun is not a director or senior management of the company but serves as the executive partner of Weiteng Partnership, which holds over 5% of the shares collectively with Wei Xiujun and his concerted actors [4]. - Chen Rui and Zhang Chun are senior management members but do not hold more than 5% of the shares individually [4]. Group 3: Transfer Plan and Pricing - The total number of shares for transfer is 3,350,936, motivated by the shareholders' funding needs [5]. - The minimum transfer price will be set at no less than 70% of the average trading price over the 20 trading days prior to July 29, 2025 [6]. - If the total valid subscriptions exceed the number of shares available, the transfer price will be determined based on a priority system of price, quantity, and time [7]. Group 4: Investor Eligibility - The transfer is open to institutional investors with appropriate pricing capabilities and risk tolerance, including securities companies, fund management companies, and qualified foreign institutional investors [8][9]. - Other private fund managers registered with the Asset Management Association of China may also participate if their products are properly filed [9]. Group 5: Company Status and Risks - The company does not face any operational risks or potential changes in control due to this transfer [9]. - There are no undisclosed significant matters affecting the company at this time [9].

Core Viewpoint - The company, Yuandong Biopharmaceutical Co., Ltd., is planning a non-public transfer of shares amounting to 3,369,550 shares, which represents 1.91% of its total share capital, to institutional investors through a pricing inquiry process [2][5]. Group 1: Share Transfer Details - The shareholders participating in the share transfer are Chengdu Nanyuan Investment Partnership, Chengdu Zhuyuan Investment Partnership, and Chengdu Juyuan Investment Partnership [2]. - The controlling shareholder and actual controller of the company will not participate in this share transfer, ensuring that their shares remain intact [2][3]. - The transfer is being organized by CITIC Securities, and the shares have been released from any restrictions, confirming clear ownership [3][4]. Group 2: Pricing and Transfer Conditions - The total number of shares to be transferred is 3,369,550, with the transfer price being set at a minimum of 70% of the average trading price over the 20 trading days prior to July 22, 2025 [5][6]. - The transfer process will prioritize price, quantity, and time of submission for determining the allocation of shares among interested institutional investors [7]. Group 3: Investor Eligibility - Eligible investors for this share transfer include institutional investors with appropriate pricing capabilities and risk tolerance, such as securities companies, fund management companies, and qualified foreign institutional investors [8]. Group 4: Company Status and Risks - The company does not face any operational risks or potential changes in control due to this share transfer, and there are no other undisclosed significant matters [9].

Core Viewpoint - Shanghai Kai Bao Pharmaceutical Co., Ltd. has reduced its shareholding in Shanghai Yi Zhong Pharmaceutical Co., Ltd. from 11.95% to 10.95% through a block transfer of 2,067,037 shares at a price of 53.98 yuan per share, which constitutes a 1% change in equity [1][3][5]. Shareholding Changes - After the transfer, Shanghai Kai Bao will hold 1,047,642 shares, representing 0.99% of the total share capital of Shanghai Yi Zhong [2][4]. - Prior to the transfer, Shanghai Kai Bao's shareholding was 12.01% of the total share capital [2][3]. Transfer Details - The total share capital of Shanghai Yi Zhong is 143,888,000 shares after a capital increase [2][4]. - The transfer was conducted through an inquiry process, with 11 institutional investors submitting valid bids, resulting in 8 investors being allocated shares [7][8]. Regulatory Compliance - The transfer process adhered to relevant laws and regulations, ensuring fairness and compliance with market standards [8].

Core Viewpoint - The company Kaisheng New Materials (301069.SZ) is planning a shareholder inquiry transfer of 20 million shares, representing 4.75% of its total share capital, primarily due to the financial needs of its major shareholder, Huabang Health (002004) [1][2]. Group 1: Shareholder Transfer Details - The total number of shares to be transferred by Huabang Health is 20,000,000, which constitutes 4.75% of Kaisheng New Materials' total share capital and 10.68% of Huabang Health's holdings [2]. - The transfer will not occur through centralized bidding or block trading, and the acquiring party must be an institutional investor with appropriate pricing and risk-bearing capabilities [2]. Group 2: Company Financials and Fundraising - Kaisheng New Materials raised a total of 310.20 million yuan from its initial public offering (IPO) in 2021, with a net amount of 281.89 million yuan, which was 26.81 million yuan less than originally planned [3]. - The company intended to raise 550 million yuan for various projects, including the expansion of a 20,000-ton aromatic polymer monomer facility and a 2,000-ton/year polyether ketone resin project [3]. - The total fundraising amount from two rounds of financing is 960.20 million yuan [5]. Group 3: Convertible Bond Issuance - Kaisheng New Materials has been approved to publicly issue convertible bonds totaling 650 million yuan, with each bond having a face value of 100 yuan [4]. - As of December 5, 2023, the company had issued 6.5 million convertible bonds, and the actual funds received amounted to approximately 639.73 million yuan after deducting underwriting fees [4].

Group 1 - The core point of the news is that Alliance Electronics (688311.SH) has announced a shareholder inquiry transfer plan, involving the transfer of 6,186,900 shares, which accounts for 3.68% of the total share capital [1] - The transferring shareholders include Chengdu Rongtou Innovation Investment Co., Ltd., Nanjing Alliance Zhihhe Enterprise Management Partnership (Limited Partnership), Xiang Rong, Nanjing Alliance Chuanghe Enterprise Management Partnership (Limited Partnership), and Liu Rong [1] - The transfer will not occur through centralized bidding or block trading, and the transferee must be an institutional investor with appropriate pricing capability and risk tolerance [1] Group 2 - In the first quarter of 2023, 2024, and 2025, Alliance Electronics reported revenues of 331 million yuan, 139 million yuan, and 21 million yuan respectively, with net profits attributable to shareholders of -56 million yuan, -272 million yuan, and -15 million yuan [2] - The operating cash flow for the same periods was -86 million yuan, -302 million yuan, and -17 million yuan respectively [2] - The company experienced a significant decline in revenue, with a year-on-year decrease of 57.94% in 2024 compared to 2023 [3] Group 3 - Alliance Electronics was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 31, 2020, with an issuance of 28.67 million shares at a price of 41.58 yuan per share, raising a total of 1.192 billion yuan [4] - The net amount raised after deducting issuance costs was 1.054 billion yuan, which was 546 million yuan more than the original plan [4] - The company plans to use the raised funds for satellite navigation and communication product industrialization projects, a technology research center, and to supplement working capital [4] Group 4 - The total fundraising amount since the listing is 1.49 billion yuan, with the company planning a stock dividend distribution of 4 shares for every 10 shares held, without cash dividends or bonus shares for the 2022 fiscal year [6] - The company issued convertible bonds to unspecified investors in 2023, raising a total of 300 million yuan, with a net amount of approximately 294.73 million yuan after deducting issuance costs [5]